ANATARA LIFESCIENCES LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.048 AUD | +4.35% |
|
+23.08% | +118.18% |
| Apr. 09 | Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial | MT |
| Feb. 28 | Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: Giugno | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 31.38 | 12.6 | 6.481 | 10.89 | 3.925 | 3.358 |
| Enterprise Value (EV) 1 | 23.64 | 7.19 | 3.799 | 7.535 | 2.82 | 2.957 |
| P/E ratio | -8.79 x | -4.39 x | -1.92 x | -4.87 x | -1.54 x | -1.35 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 23.3 x | 19 x | - | - | - | - |
| EV / Revenue | 17.6 x | 10.8 x | - | - | - | - |
| EV / EBITDA | -6.4 x | -2.41 x | -1.08 x | -3.7 x | -1.11 x | -1.46 x |
| EV / FCF | -9.5 x | -11.5 x | -2.41 x | -5.43 x | -2.22 x | -1.93 x |
| FCF Yield | -10.5% | -8.71% | -41.6% | -18.4% | -45% | -51.7% |
| Price to Book | 3.65 x | 2.13 x | 2.27 x | 2.84 x | 2.88 x | 3.63 x |
| Nbr of stocks (in thousands) | 49,413 | 49,413 | 49,856 | 70,239 | 71,356 | 119,924 |
| Reference price 2 | 0.6350 | 0.2550 | 0.1300 | 0.1550 | 0.0550 | 0.0280 |
| Announcement Date | 8/31/18 | 8/26/19 | 8/24/20 | 8/23/21 | 8/29/22 | 8/23/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Giugno | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.345 | 0.6634 | - | - | - | - |
| EBITDA 1 | -3.693 | -2.988 | -3.502 | -2.037 | -2.53 | -2.02 |
| EBIT 1 | -3.714 | -3.011 | -3.518 | -2.042 | -2.535 | -2.045 |
| Operating Margin | -276.2% | -453.84% | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.569 | -2.868 | -3.365 | -1.996 | -2.532 | -2.023 |
| Net income 1 | -3.569 | -2.868 | -3.365 | -1.996 | -2.532 | -2.023 |
| Net margin | -265.43% | -432.36% | - | - | - | - |
| EPS 2 | -0.0722 | -0.0580 | -0.0677 | -0.0318 | -0.0356 | -0.0207 |
| Free Cash Flow 1 | -2.487 | -0.6265 | -1.579 | -1.388 | -1.269 | -1.53 |
| FCF margin | -184.98% | -94.44% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/31/18 | 8/26/19 | 8/24/20 | 8/23/21 | 8/29/22 | 8/23/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 7.74 | 5.41 | 2.68 | 3.35 | 1.1 | 0.4 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -2.49 | -0.63 | -1.58 | -1.39 | -1.27 | -1.53 |
| ROE (net income / shareholders' equity) | -34.6% | -39.6% | -76.7% | -59.7% | -97.5% | -177% |
| ROA (Net income/ Total Assets) | -21% | -23.2% | -45.2% | -33.3% | -52% | -80.2% |
| Assets 1 | 17.01 | 12.34 | 7.441 | 5.997 | 4.87 | 2.522 |
| Book Value Per Share 2 | 0.1700 | 0.1200 | 0.0600 | 0.0500 | 0.0200 | 0.0100 |
| Cash Flow per Share 2 | 0.0300 | 0.0300 | 0.0500 | 0.0500 | 0.0200 | 0 |
| Capex 1 | 0.02 | - | 0 | 0 | 0.01 | 0 |
| Capex / Sales | 1.72% | - | - | - | - | - |
| Announcement Date | 8/31/18 | 8/26/19 | 8/24/20 | 8/23/21 | 8/29/22 | 8/23/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +118.18% | 5.26M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ANR Stock
- Financials Anatara Lifesciences Ltd
